Showing results (461-470 of 477) with videos related to

Sort By:
Pageof 48
Molecular Cancer Research : MCR|August 31, 2017
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung CancerZachary A Yochum, Jessica Cades, Lucia Mazzacurati, et al.
International Journal of Sport Nutrition and Exercise Metabolism|December 30, 2025
Navigating the Risks Beyond the Label: Unpacking Global Nutritional Supplement SafetyFloris C Wardenaar, Stephen F Burns, Marcus Campos, et al.
Future Oncology (London, England)|April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
Plos Genetics|June 2, 2012
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesisPhuoc T Tran, Emelyn H Shroff, Timothy F Burns, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
JCI Insight|July 7, 2026
SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in micePadraig E Hawkins, Sarah R Leist, Hong Dang, et al.
Molecular Cancer Research : MCR|August 29, 2013
The twist box domain is required for Twist1-induced prostate cancer metastasisRajendra P Gajula, Sivarajan T Chettiar, Russell D Williams, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
HIV Medicine|June 6, 2024
Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to menJ Hutchinson, B Neesgard, J Kowalska, et al.
Pageof 48